Loading...
XNASALKS
Market cap4.81bUSD
Dec 20, Last price  
29.71USD
1D
-0.87%
1Q
4.06%
Jan 2017
-46.55%
Name

Alkermes Plc

Chart & Performance

D1W1MN
XNAS:ALKS chart
P/E
13.51
P/S
2.89
EPS
2.20
Div Yield, %
0.00%
Shrs. gr., 5y
1.82%
Rev. gr., 5y
8.74%
Revenues
1.66b
+49.61%
39,054,01776,126,000166,601,000239,965,000240,717,000326,839,000178,281,000186,640,000389,977,000575,548,000618,789,000628,335,000745,694,000903,374,0001,094,274,0001,170,947,0001,038,756,0001,173,751,0001,111,795,0001,663,405,000
Net income
356m
P
-102,384,561-73,916,0003,818,0009,445,000166,979,000130,505,000-39,626,000-45,540,000-113,678,00024,983,000-30,061,000-227,163,000-208,444,000-157,945,000-139,311,000-196,620,000-110,861,000-48,169,000-158,267,000355,757,000
CFO
401m
+1,807.21%
-98,249,224-74,255,000116,530,00083,727,00042,424,00034,590,000-12,247,000-5,906,000-2,482,000126,551,00011,139,000-40,360,000-63,802,00019,190,00099,281,00072,077,00082,842,000101,715,00021,044,000401,353,000
Earnings
May 30, 2025

Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
URL
https://www.alkermes.com/
IPO date
Jul 16, 1991
Employees
2,280
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,663,405
49.61%
1,111,795
-5.28%
1,173,751
13.00%
Cost of revenue
1,249,283
1,202,701
1,165,910
Unusual Expense (Income)
NOPBT
414,122
(90,906)
7,841
NOPBT Margin
24.90%
0.67%
Operating Taxes
(97,638)
(9,037)
8,863
Tax Rate
113.03%
NOPAT
511,760
(81,869)
(1,022)
Net income
355,757
-324.78%
(158,267)
228.57%
(48,169)
-56.55%
Dividends
Dividend yield
Proceeds from repurchase of equity
(11,714)
1,426
8,748
BB yield
0.25%
-0.03%
-0.23%
Debt
Debt current
8,746
3,000
3,000
Long-term debt
444,894
395,821
413,206
Deferred revenue
10,701
11,491
Other long-term liabilities
49,878
132,213
136,319
Net debt
(359,738)
(472,864)
(578,965)
Cash flow
Cash from operating activities
401,353
21,044
101,715
CAPEX
(48,048)
(38,255)
(29,020)
Cash from investing activities
53,357
(64,541)
(66,204)
Cash from financing activities
(289,714)
(1,574)
29,072
FCF
345,276
(35,703)
(9,116)
Balance
Cash
773,491
740,075
765,741
Long term investments
39,887
131,610
229,430
Excess cash
730,208
816,095
936,483
Stockholders' equity
(1,344,912)
(1,708,484)
(1,543,083)
Invested Capital
2,969,661
3,188,421
3,099,281
ROIC
16.62%
ROCE
25.49%
0.50%
EV
Common stock shares outstanding
169,730
163,541
160,942
Price
27.74
6.16%
26.13
12.34%
23.26
16.59%
Market cap
4,708,310
10.18%
4,273,326
14.15%
3,743,511
18.16%
EV
4,348,572
3,800,462
3,164,546
EBITDA
489,049
(13,044)
86,493
EV/EBITDA
8.89
36.59
Interest
23,032
13,040
11,219
Interest/NOPBT
5.56%
143.08%